QYLD vs XBI
Global X Nasdaq 100 Covered Call ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.60% for QYLD.
- • QYLD pays a higher dividend yield (5.97%).
Side-by-side metrics
| Metric | QYLD | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.60% | 0.35% |
Dividend yield Trailing 12-month yield. | 5.97% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $8.20B | $10.92B |
YTD return | 10.56% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.47 | 1.01 |
P/E ratio | 28.74 | — |
Last price | $18.06 | $156.41 |
Inception | — | — |
Issuer | Global X | State Street |
QYLD top holdings
| AAPL | Apple Inc | 8.24% |
| NVDA | NVIDIA Corp | 8.08% |
| MSFT | Microsoft Corp | 6.35% |
| MU | Micron Technology Inc | 4.52% |
| AMZN | Amazon.com Inc | 4.25% |
| AMD | Advanced Micro Devices Inc | 3.73% |
| TSLA | Tesla Inc | 3.44% |
| META | Meta Platforms Inc Class A | 3.00% |
| WMT | Walmart Inc | 2.72% |
| GOOGL | Alphabet Inc Class A | 2.69% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About QYLD
QYLD (Global X Nasdaq 100 Covered Call ETF) is Nasdaq-100 covered call income strategy. Managed by Global X, the fund carries $8.2B in assets under management, an expense ratio of 0.60%, a dividend yield of 5.97%. Its largest holding is Apple Inc (AAPL), which represents 8.2% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 11.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.